The DLE mutation (Ser239Asp/Ile332Glu/Ala330Leu) in the IgG Fc region is a crucial modification in antibody engineering designed to optimize antibody effector functions and stability. This mutation enhances the binding to FcgammaRIIIa by introducing additional hydrogen bonds that separate the CH2 domain of the Fc segment. Consequently, it significantly boosts antibody-dependent cell-mediated cytotoxicity (ADCC), bolstering the cytotoxic effect of natural killer (NK) cells on target cells. The Ala330Leu substitution within the DLE mutation reduces binding to complement protein C1q, thereby diminishing complement-dependent cytotoxicity (CDC) mediated by the antibody, which helps mitigate non-specific inflammatory responses. Introducing the DLE mutation into the antibodys heavy chain also markedly enhances its stability and solubility. This mutation has been successfully applied in optimizing various therapeutic antibodies, markedly improving their efficacy and stability.
Reinheit:
>95% Determined by SDS-PAGE
Anwendungsbeschreibung:
Cross-Reactivity: <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
